National Toxicology Program

National Toxicology Program
https://ntp.niehs.nih.gov/go/18977

Target Organs and Levels of Evidence for GMM-05

Toxicology Studies of Bromodichloromethane (CASRN 75-27-4) in Genetically Modified (FVB Tg.AC Hemizygous) Mice (Dermal, Drinking Water, and Gavage Studies) and Carcinogenicity Studies of Bromodichloromethane in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Drinking Water and Gavage Studies)

Chemical (Study Title)
CASRN
Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
Water disinfection model (Bromodichloromethane)
75-27-4
09/27/2005 Solvent. Chemical intermediate. Flame retardant. Special initiative using the transgenic mouse model in methods development. Topical Application
0, 64, 128, and 256 mg/kg
Battelle Columbus Laboratory

Levels of evidence information for Dermal and Genetic Toxicology Studies of Bromodichloromethane in Tg.AC Hemizygous Mice
  Male Tg.AC Hemizygous Mice Female Tg.AC Hemizygous Mice
  26 Weeks 39 Weeks 26 Weeks 39 Weeks
Neoplastic Lesions None None None None
Non-Neoplastic Lesions None None None None




Chemical (Study Title)
CASRN
Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
Water disinfection model (Bromodichloromethane)
75-27-4
09/27/2005 Solvent. Chemical intermediate. Flame retardant. Special initiative using the transgenic mouse model in methods development. Dosed-Water
0, 175, 350, or 700 mg/L
Battelle Columbus Laboratory

Levels of evidence information for Drinking Water and Genetic Toxicology Studies of Bromodichloromethane in p53 Haploinsufficient Mice
  Male P53 +/- (C57BL/6) Mice Female P53 +/- (C57BL/6) Mice
  26 Weeks 42 Weeks 26 Weeks 42 Weeks
Levels of Evidence No Evidence No Evidence No Evidence No Evidence
Neoplastic Lesions None None None None
Non-Neoplastic Lesions
  • Kidney: tubule degeneration
  • Kidney: tubule degeneration
  • Liver: hepatocyte fatty change
None

Levels of evidence information for Drinking Water and Genetic Toxicology Studies of Bromodichloromethane in Tg.AC Hemizygous Mice
  Male Tg.AC (FVB/N) Hemizygous Mice Female Tg.AC (FVB/N) Hemizygous Mice
  26 Weeks 42 Weeks 26 Weeks 42 Weeks
Neoplastic Lesions None None None None
Non-Neoplastic Lesions
  • Kidney: nephropathy; tubule degeneration
  • Kidney: nephropathy
  • Liver: hepatocyte fatty change; hepatocyte cytoplasmic vacuolization
  • Liver: hepatocyte fatty change




Chemical (Study Title)
CASRN
Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
Water disinfection model (Bromodichloromethane)
75-27-4
09/27/2005 Solvent. Chemical intermediate. Flame retardant. Special initiative using the transgenic mouse model in methods development. Gavage
0, 25, 50, or 100 mg/kg
Battelle Columbus Laboratory

Levels of evidence information for Gavage and Genetic Toxicology Studies of Bromodichloromethane in p53 Haploinsufficient Mice
  Male P53 +/- (C57BL/6) Mice Female P53 +/- (C57BL/6) Mice
  26 Weeks 41 Weeks 26 Weeks 41 Weeks
Levels of Evidence No Evidence No Evidence No Evidence No Evidence
Neoplastic Lesions None None None None
Non-Neoplastic Lesions
  • Kidney: tubule degeneration
  • Kidney: tubule degeneration
  • Liver: hepatocyte fatty change
  • Liver: hepatocyte fatty change


Levels of evidence information for Gavage and Genetic Toxicology Studies of Bromodichloromethane in Tg.AC Hemizygous Mice
  Male Tg.AC (FVB/N) Hemizygous Mice Female Tg.AC (FVB/N) Hemizygous Mice
  26 Weeks 41 Weeks 26 Weeks 41 Weeks
Neoplastic Lesions None None
  • Forestomach: multiple squamous cell papilloma 3/15 5/15 6/15 11/15
  • Forestomach: multiple squamous cell papilloma 1/10 6/10 5/10 9/10
Non-Neoplastic Lesions
  • Kidney: tubule degeneration
  • Kidney: tubule degeneration
  • Liver: hepatocyte fatty change; hepatocyte cytoplasmic vacuolization
  • Liver: hepatocyte fatty change; hepatocyte cytoplasmic vacuolization
NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.